Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Immix Biopharma's share price for the quarter that ended in Dec. 2023 was $6.92. Immix Biopharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 19.92 Mil. Therefore, Immix Biopharma's market cap for the quarter that ended in Dec. 2023 was $137.86 Mil.
Immix Biopharma's quarterly market cap
increased
from Jun. 2023 ($43.74 Mil) to Sep. 2023 ($67.06 Mil) and
increased
from Sep. 2023 ($67.06 Mil) to Dec. 2023 ($137.86 Mil).
Immix Biopharma's annual market cap
declined
from Dec. 2021 ($47.09 Mil) to Dec. 2022 ($31.81 Mil) but then
increased
from Dec. 2022 ($31.81 Mil) to Dec. 2023 ($137.86 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Immix Biopharma's Enterprise Value for Today is $42.23 Mil.
Immix Biopharma Market Cap Historical Data
The historical data trend for Immix Biopharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Immix Biopharma's Market Cap
For the Biotechnology subindustry, Immix Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immix Biopharma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immix Biopharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Immix Biopharma's Market Cap falls into.
Immix Biopharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Immix Biopharma's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immix Biopharma (NAS:IMMX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Immix Biopharma Market Cap Related Terms
Thank you for viewing the detailed overview of Immix Biopharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Immix Biopharma (Immix Biopharma) Business Description
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. It has two business units ImmixBio and Nexcella.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IMMX has been successfully added to your 